看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 1.9x - 2.1x | 2.0x |
| Historical Pb Multiple | 1.6x - 4.4x | 3.4x |
| Fair Value | $9.48 - $10.48 | $9.98 |
| Upside | 19.6% - 32.2% | 25.9% |
| Benchmarks | - | Full Ticker |
| Dyadic International, Inc. | - | NasdaqCM:DYAI |
| Onconetix, Inc. | - | NasdaqCM:ONCO |
| Cardiff Oncology, Inc. | - | NasdaqCM:CRDF |
| Geron Corporation | - | NasdaqGS:GERN |
| Trevena, Inc. | - | PINC:TRVN |
| Day One Biopharmaceuticals, Inc. | - | NasdaqGS:DAWN |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| DYAI | ONCO | CRDF | GERN | TRVN | DAWN | |||
| NasdaqCM:DYAI | NasdaqCM:ONCO | NasdaqCM:CRDF | NasdaqGS:GERN | PINC:TRVN | NasdaqGS:DAWN | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 14.5% | -182.3% | -9.6% | 5.2% | -10.6% | 49.5% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -404.2% | -19098.5% | -7594.3% | -23982.0% | -19680.3% | -733.3% | ||
| Prior Fiscal Year | -234.4% | NA | -8496.9% | -77690.7% | 12839.7% | NA | ||
| Latest Fiscal Year | -166.2% | -63986.5% | -6655.2% | -226.7% | -1289.2% | -72.8% | ||
| Latest Twelve Months | -166.2% | -2758.7% | -6655.2% | -226.7% | -6233.7% | -72.8% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -64.3% | -167.8% | -54.9% | -70.4% | -273.1% | -56.4% | ||
| Prior Fiscal Year | -80.1% | -113.4% | -47.1% | -112.3% | -133.8% | -55.7% | ||
| Latest Twelve Months | -139.2% | -233.8% | -59.5% | -66.1% | -1918.1% | -22.5% | ||
| Next Fiscal Year | 981.3% | 159.0% | -110.5% | -35.8% | 112.4% | -33.7% | ||
| Two Fiscal Years Forward | 82.9% | 72.2% | 633.0% | -9.9% | 17.5% | -14.5% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 10.3x | 0.3x | 274.7x | 11.4x | 2.0x | 6.1x | ||
| Price / LTM EPS | -6.2x | 0.0x | -4.1x | -5.0x | 0.0x | -8.4x | ||
| Price / Book | 14.6x | 0.0x | 2.3x | 3.1x | 0.0x | 1.6x | ||
| Price / Fwd Book | -9.7x | 0.0x | 7.8x | 4.5x | 0.0x | 2.2x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | 0.0x | 2.3x | 14.6x | |||||
| Historical P/B Ratio | 1.6x | 3.4x | 4.4x | |||||
| Selected P/B Multiple | 1.9x | 2.0x | 2.1x | |||||
| (x) Book Value | 503 | 503 | 503 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | DYAI | ONCO | CRDF | GERN | TRVN | DAWN | |
| Value of Common Equity | 36 | 1 | 188 | 879 | 1 | 804 | |
| (/) Shares Outstanding | 30.1 | 8.3 | 66.5 | 636.9 | 0.9 | 101.4 | |
| Implied Stock Price | 1.20 | 0.07 | 2.82 | 1.38 | 1.28 | 7.93 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 1.20 | 0.07 | 2.82 | 1.38 | 1.28 | 7.93 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |